Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - Jefferies raised its price target on Insmed (NASDAQ:INSM) to $148.00 from $129.00 on Tuesday, maintaining a Buy rating following FDA approval of the company’s bronchiectasis treatment. The company, now valued at $25.59 billion, has demonstrated strong momentum with a 63.51% return year-to-date and maintains healthy financials with a robust gross margin of 75.72%.
The FDA approved Insmed’s Brinsupri for bronchiectasis, an untapped market, with what Jefferies described as a "best-case scenario" label that includes both 10mg and 25mg doses without requiring patients to have a history of exacerbations.
Insmed has priced the treatment at $88,000 per year, which Jefferies indicated is in line with expectations and should not face significant reimbursement challenges.
Jefferies views Insmed as "an attractive commercial biotech story in pulmonary space" with a track record of clinical success, now bolstered by this latest regulatory approval.
The investment firm expects Insmed shares can "grind higher" based on the execution of the Brinsupri launch and upcoming Phase 2 data for CRSsNP expected by year-end.
In other recent news, Insmed Incorporated reported its second-quarter 2025 earnings, revealing a revenue of $107.4 million, which surpassed the forecast of $103.41 million. However, the company experienced a larger-than-expected loss per share, with an EPS of negative $1.70 compared to the anticipated negative $1.30. In a significant development, the FDA approved BRINSUPRI (brensocatib), making it the first treatment for non-cystic fibrosis bronchiectasis, a condition affecting around 500,000 diagnosed patients in the U.S. This approval marks a milestone for Insmed as it becomes the first FDA-approved therapy specifically targeting this progressive lung disease.
Additionally, RBC Capital raised its price target for Insmed to $120 from $108, maintaining an Outperform rating. This decision was influenced by the growing anticipation surrounding the potential launch of Insmed’s drug brenso later this year. Jefferies also increased its price target to $129 from $123, maintaining a Buy rating, and highlighted the upcoming PDUFA date for brensocatib scheduled for August 12, 2025. Both firms expressed confidence in Insmed’s strategic groundwork with payers, patients, and physicians ahead of the launch.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.